Development of Café-Au-Lait-Macule Lesions in a Patient After Dupilumab Therapy for Atopic Dermatitis.
atopic dermatitis
café-au-lait macules
dermatology
dupilumab
dupilumab dermatologic reaction
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
accepted:
26
07
2023
medline:
29
8
2023
pubmed:
29
8
2023
entrez:
29
8
2023
Statut:
epublish
Résumé
Atopic dermatitis (AD) is a chronic immune-mediated disease characterized by intense pruritis, causing inflammation, itching, and redness of the skin. Dupilumab is a human monoclonal antibody that has been approved for the treatment of atopic dermatitis. It has also been linked with various adverse effects, most of them confined to the injection site. Café-au-lait-macules are benign pigmented lesions of the skin, usually seen in people with genetic disorders. We present a case of café-au-lait macules as an adverse effect of dupilumab therapy in a patient with atopic dermatitis. The patient in this case had been receiving dupilumab therapy for atopic dermatitis. The eczematous lesions had seen improvement; however, the patient presented with CALMs on follow-up, which seem to be linked with dupilumab therapy.
Identifiants
pubmed: 37641759
doi: 10.7759/cureus.42581
pmc: PMC10460293
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e42581Informations de copyright
Copyright © 2023, Hasanain et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Pediatr Health Care. 2020 Jan - Feb;34(1):71-81
pubmed: 31831114
J Drugs Dermatol. 2022 Mar 1;21(3):311-312
pubmed: 35254760
Cureus. 2020 Apr 6;12(4):e7565
pubmed: 32382467
Case Rep Dermatol. 2022 Nov 30;14(3):356-361
pubmed: 36655064
N Engl J Med. 2014 Jul 10;371(2):130-9
pubmed: 25006719
N Engl J Med. 2016 Dec 15;375(24):2335-2348
pubmed: 27690741